Callisto Pharmaceuticals, Inc., is a publicly traded biotechnology company on the OTC Bulletin Board (CLSP.OB). The company has novel candidates in the pipeline for therapeutic intervention of multiple myeloma, colon cancer and for gastrointestinal inflammation. The company is also developing, in collaboration with the Rockefeller University, innovative therapeutic products for bioterrorism defense.

Callisto Pharmaceuticals submitted an IND in September 2003 for clinical evaluation of Atiprimod for multiple myeloma. This trial is anticipated to begin in December 2003. Atiprimod is a novel anti-angiogenic and cytotoxic agent that also has considerable potential in treatment of other cancers.